StreetInsider.com News Articles

Form 4 BioAtla, Inc. For: Feb 28 Filed by: SHORT JAY M PHD

Mon, 02 Mar 2026 18:15:00 -0500

si-local-file:///var/storage/secattach/20260302/26094348.html

Form 4 BioAtla, Inc. For: Feb 28 Filed by: SHORT JAY M PHD

Mon, 02 Mar 2026 18:15:00 -0500

si-local-file:///var/storage/secattach/20260302/26094348.html

Form 4 BioAtla, Inc. For: Feb 28 Filed by: Sievers Eric

Mon, 02 Mar 2026 18:14:00 -0500

si-local-file:///var/storage/secattach/20260302/26094343.html

Form 4 BioAtla, Inc. For: Feb 28 Filed by: Sievers Eric

Mon, 02 Mar 2026 18:14:00 -0500

si-local-file:///var/storage/secattach/20260302/26094343.html

Form 4 BioAtla, Inc. For: Feb 28 Filed by: WALDRON RICHARD A

Mon, 02 Mar 2026 18:14:00 -0500

si-local-file:///var/storage/secattach/20260302/26094344.html

Form 4 BioAtla, Inc. For: Feb 28 Filed by: WALDRON RICHARD A

Mon, 02 Mar 2026 18:14:00 -0500

si-local-file:///var/storage/secattach/20260302/26094344.html

Form 4 BioAtla, Inc. For: Feb 28 Filed by: Vasquez Christian

Mon, 02 Mar 2026 18:14:00 -0500

si-local-file:///var/storage/secattach/20260302/26094347.html

Form 4 BioAtla, Inc. For: Feb 28 Filed by: Vasquez Christian

Mon, 02 Mar 2026 18:14:00 -0500

si-local-file:///var/storage/secattach/20260302/26094347.html

Form DEFA14A BioAtla, Inc.

Mon, 02 Mar 2026 07:42:00 -0500

si-local-file:///var/storage/secattach/20260302/26087080.html

Form DEFA14A BioAtla, Inc.

Mon, 02 Mar 2026 07:42:00 -0500

si-local-file:///var/storage/secattach/20260302/26087080.html

Form 8-K BioAtla, Inc. For: Feb 24

Mon, 02 Mar 2026 07:41:00 -0500

si-local-file:///var/storage/secattach/20260302/26087075.html

Form 8-K BioAtla, Inc. For: Feb 24

Mon, 02 Mar 2026 07:41:00 -0500

si-local-file:///var/storage/secattach/20260302/26087075.html

BioAtla explores asset sale, cuts workforce by 70%

Mon, 02 Mar 2026 07:30:57 -0500

BioAtla Inc. (NASDAQ: BCAB) announced its board of directors initiated a formal process to evaluate strategic options to maximize shareholder value, including potential asset sales, licensing transactions, strategic partnerships or other corporate transactions.

The clinical-stage biotechnology company, which develops Conditionally Active Biologic antibody therapeutics for solid tumors, is simultaneously implementing a restructuring plan that includes reducing its workforce by approximately 70% and expanding cost-containment measures. The company said it intends to retain employees essential for supporting value creation during the strategic review.

BioAtla has engaged Tungsten Advisors as its exclusive strategic financial advisor for the process. The company stated there is no

BioAtla explores asset sale, cuts workforce by 70%

Mon, 02 Mar 2026 07:30:57 -0500

BioAtla has engaged Tungsten Advisors as its exclusive strategic financial advisor for the process. The company stated there is no

BioAtla explores asset sale, cuts workforce by 70%

Mon, 02 Mar 2026 07:30:57 -0500

BioAtla has engaged Tungsten Advisors as its exclusive strategic financial advisor for the process. The company stated there is no

BioAtla explores asset sale, cuts workforce by 70%

Mon, 02 Mar 2026 07:30:57 -0500

BioAtla has engaged Tungsten Advisors as its exclusive strategic financial advisor for the process. The company stated there is no

BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

Mon, 02 Mar 2026 07:30:00 -0500

SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, announced that the Board of Directors has initiated a formal process to explore and evaluate strategic options to maximize shareholder value, including the sale of preclinical and clinical assets, licensing transactions, strategic partnerships or other corporate transactions. Concurrently, the Company is implementing a restructuring plan to significantly reduce operating expenses, including a workforce reduction of approximately 70% and expansion of

BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

Mon, 02 Mar 2026 07:30:00 -0500

BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

Mon, 02 Mar 2026 07:30:00 -0500

BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

Mon, 02 Mar 2026 07:30:00 -0500

Form DEFM14A BioAtla, Inc.

Wed, 11 Feb 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260211/25983207.html

Form DEFM14A BioAtla, Inc.

Wed, 11 Feb 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260211/25983207.html

Form 8-K BioAtla, Inc. For: Feb 08

Mon, 09 Feb 2026 06:03:00 -0500

si-local-file:///var/storage/secattach/20260209/25964301.html

Form 8-K BioAtla, Inc. For: Feb 08

Mon, 09 Feb 2026 06:03:00 -0500

si-local-file:///var/storage/secattach/20260209/25964301.html

Form 8-K BioAtla, Inc. For: Feb 06

Fri, 06 Feb 2026 17:02:00 -0500

si-local-file:///var/storage/secattach/20260206/25962544.html